ArticleJournal of magnetic resonance imaging : JMRI2025
Diagnostic Accuracy of
Article in Journal of magnetic resonance imaging : JMRI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Canadian radiology: 2025 update.Japanese journal of radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEdited MRS technique such as MEshcher-GArwood Point RESolved Spectroscopy (MEGA-PRESS) can determine isocitrate dehydrogenase mutation (IDH) mutation status in patients with gliomas but its accuracy in assessing glioma grade has not yet been formally evaluated. PURPOSE: To evaluate the diagnostic accuracy of metabolites such as lactate obtained from the PRESS and MEGA-PRESS sequences in the preoperative grading of glioma. To assess the prognostic value of those metabolite ratios in the overall survival of patients with gliomas. STUDY TYPE: Prospective. SUBJECTS: Sixty-nine subjects with gliomas (16 grade 2, 21 grade 3, and 32 grade 4). Mean age was 50.5 ± 16.7 years; 38 were male and 31 were female. FIELD STRENGTH/SEQUENCE: 3 T/MEGA-PRESS, PRESS. ASSESSMENT: Single voxel PRESS and MEGA-PRESS spectra were obtained from tumors in patients undergoing preoperative MRI. Several tumor metabolites were measured from the PRESS, MEGA-PRESS edit-off, and difference spectra using LCModel (Linear Combination of Model Spectra) software. Diagnosis and glioma grading was done using the World Health Organization (WHO) 2016 classification. Overall survival was assessed. STATISTICAL TESTS: Diagnostic accuracy was measured using receiver-operating characteristic (ROC) curve. Univariate and multivariate Cox proportional hazards modeling was used for the assessment of prognostic factors for time to death.
resultsIn the differentiation between low- vs. high-grade gliomas, tCr/tCho ratios obtained from PRESS and MEGA-PRESS sequences had similar accuracies (area under the ROC curves [AUCs] = 0.71) while Lac/NAA from PRESS had a lower accuracy (AUC = 0.65). The presence of a detectable 2-hydroxyglutarate peak on the difference spectrum was a favorable prognostic factor in univariate analysis (hazard ratio = 0.25, 95% confidence interval: 0.08-0.83). No other metabolite was found to be a significant prognostic factor in univariate and multivariate analyses. DATA
conclusionEdited MRS can be used to detect metabolites which can help in the preoperative grading of gliomas and in determination of the overall survival. A separate PRESS acquisition is needed for lactate quantification. PLAIN LANGUAGE SUMMARY: Gliomas are brain tumors that vary in severity. This study explored the use of two advanced MR spectroscopy techniques (PRESS and MEGA-PRESS) in detecting tumor metabolites. The authors found that both techniques' choline/creatine ratio showed moderate accuracy in identifying high-grade gliomas. Lactate was better revealed with the PRESS technique and was associated with high-grade gliomas. They confirmed that the MEGA-PRESS technique allowed additional detection of 2-hydroxyglutarate in IDH-mutant gliomas, which was linked to better survival. These findings emphasize that advanced MR spectroscopy can extract metabolic information time-efficiently, which can be used to improve the preoperative diagnosis of patients with gliomas. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.